The Therapy · UK Information
Enterra Therapy is the first and only therapy approved in Europe specifically for chronic, medication-resistant nausea and vomiting associated with gastroparesis – delivered by a small implanted gastric stimulator.
On this page: how the therapy works, who it is for, what the implantation involves – and how to find out whether it could be right for you. Free, no-obligation enquiry at a UK partner clinic.
Sending an enquiry is free. Private consultation fees apply only if you decide to book an appointment with the consultant.
A specialist team will get back to you within 1–2 working days. No obligation, no cost.
Talk to a specialist today – free and confidential.
Simply fill out the form, and one of our team will get back to you to discuss your options. No obligation, no pressure.
Your information is confidential and will not be shared.
We strictly respect the rules of the GDPR.
* mandatory fields
Confidential. GDPR-compliant. Privacy.
What is it?
Enterra® Therapy is designed for patients whose gastroparesis symptoms persist despite dietary adjustments, medications and lifestyle changes. At its heart lies a small implantable stimulator, placed under the skin in the abdomen and connected to leads positioned on the stomach wall.
This device delivers gentle electrical impulses that modulate the stomach's neuromuscular activity, improving motility and reducing symptoms such as nausea and vomiting. The therapy was developed after recognition that when nerves controlling the stomach – in particular the vagus nerve – are damaged or underperforming, muscle contractions of the stomach become weak and uncoordinated.
By providing targeted stimulation, the Enterra system seeks to restore more normal gastric emptying, relieve discomfort and improve nutritional absorption.
Who is it for?
Enterra® Therapy is indicated in Europe for adults aged 18 to 70 years with chronic, medication-resistant nausea and vomiting associated with gastroparesis. Suitability is established through a multidisciplinary assessment.
Ideal candidates often include people with diabetic gastroparesis where nerve damage has been documented, post-surgical gastroparesis after stomach or vagus-nerve surgery, and idiopathic gastroparesis when symptoms are refractory.
How does it work?
Once the device is implanted, leads are positioned on the gastric wall and the stimulator beneath the abdominal skin delivers programmed impulses at specific frequencies, durations and amplitudes. These impulses engage neural circuits and smooth muscle within the stomach, improving the coordination of contractions and accelerating gastric emptying.
When the stomach empties more effectively, symptoms such as persistent nausea, vomiting and early fullness often become milder, allowing improved meal consumption and better nutritional intake. At the same time the therapy can reduce the distension and discomfort caused by retained gastric food.
The treatment does not rely solely on the device. After implantation, patients attend regular follow-up to adjust stimulation parameters, review symptom diaries and work with dietitians to optimise meal patterns.
The journey
A typical Enterra® Therapy pathway in four stages.
Comprehensive multidisciplinary evaluation: gastric emptying study, symptom scoring, nutritional status, surgical and anaesthetic review.
A minimally invasive (usually laparoscopic) procedure under general anaesthetic. Hospital stays are short and recovery comparatively quick.
The device is activated and the stimulation parameters fine-tuned at follow-up appointments – tailored to your symptoms and response.
Ongoing dietitian support, symptom diaries and regular reviews. Some patients see rapid improvement; others gradually over months.
Outcomes & expectations
Enterra® Therapy has shown beneficial outcomes in many patients, but it is important to set realistic expectations. Some people experience rapid improvement in symptoms; others gradually over months. A small proportion may require additional interventions (for example pyloroplasty or other surgical options) if stomach emptying remains severely impaired.
Success requires adherence: smaller meals, low-fat and low-fibre diets, avoidance of foods that delay gastric emptying and modest physical activity after meals (gentle walking) all support the therapy's effectiveness. For patients with diabetic gastroparesis, controlling blood glucose remains crucial, as poor glycaemic control undermines gastric motility.
The therapy is not a cure for gastroparesis. It is a sophisticated assistive technology that supports your stomach's natural function, complements medical and dietary care, and gives you a chance for more confident eating, fewer hospital visits and improved quality of life.
UK Partner Clinics
Two specialist centres of excellence offering Enterra® Therapy. Pick whichever location is more convenient – or use the general enquiry above and we'll guide you.
Manchester
Mr Paul Goldsmith, Consultant General Surgeon · specialising in upper-GI motility & gastroparesis.
Visit clinic page
Kent
Mr Nick Boyle, Consultant Surgeon · among the first to use Enterra® Therapy in the UK.
Visit clinic pageFrequently asked questions
Free of charge. No obligation. The first conversation with a UK specialist is the most important step on your journey.
Request free information →Specialist information sites operated by the Episkepsis network.